DiaMedica Therapeutics, Inc. (DMAC) vs Opus Genetics, Inc. (IRD)
DiaMedica Therapeutics, Inc. and Opus Genetics, Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and Opus Genetics, Inc. are of similar size ($422.2M and $405.2M). DiaMedica Therapeutics, Inc. has the higher net margin (0.00% vs −1,091.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, DiaMedica Therapeutics, Inc. leads on 7 and Opus Genetics, Inc. on 5.
Valuation
Profitability
| Metric | DMAC | IRD | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (513.47%) | 0.00% |
| Net margin | 0.00% | (1,091.82%) | 0.00% |
| Free cash flow margin | 0.00% | (412.61%) | 0.00% |
| Return on equity | (114.62%) | (4,796.52%) | (57.72%) |
| Return on assets | (98.18%) | (163.50%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack